skip to main content
Show Results with:

Results 1 - 10 of 39  for Everything in this catalogue

results 1 2 3 4 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Material Type:
Article
Add to My workspace

Medical Education Partnership Initiative in Zimbabwe: partnerships for transformation

Hakim, James G et al.

The lancet. Global health. Volume 5:Issue 2 (2017); pp e143-e144 -- Elsevier

Online access

2
Material Type:
Article
Add to My workspace

Medical Education Partnership Initiative in Zimbabwe: partnerships for transformation

Hakim, James G et al.

The lancet -- Elsevier -- Volume: 5 2;e144) -- 2017

Online access

3
Material Type:
Article
Add to My workspace

Medical Education Partnership Initiative in Zimbabwe: partnerships for transformation

Hakim, James G et al.

The lancet -- Elsevier -- Volume: 5 2;e144) -- 2017

Online access

4
Material Type:
Article
Add to My workspace

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy

Singini, Isaac et al.

HIV clinical trials. Volume 17:Issue 5 (2016); pp 173-180 -- Taylor & Francis, Taylor & Francis Group

Online access

5
Material Type:
Article
Add to My workspace

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy

Singini, Isaac et al.

HIV clinical trials. Volume 17:Issue 5 (2016); pp 173-180 -- Taylor & Francis, Taylor & Francis Group

Online access

6
Material Type:
Article
Add to My workspace

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Hakim, James G et al.

The Lancet infectious diseases. Volume 18:Number 1 (2018, January); pp 47-57 -- Elsevier Science

Online access

7
Material Type:
Article
Add to My workspace

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Hakim, James G et al.

The Lancet infectious diseases -- Elsevier Science -- Volume: 18 Issue: 1; (pages 47-57) -- 2018

Online access

8
Material Type:
Article
Add to My workspace

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Hakim, James G et al.

The Lancet infectious diseases. Volume 18:Issue 1 (2018); pp 47-57 -- Elsevier Science

Online access

9
Material Type:
Article
Add to My workspace

HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052

Palumbo, Philip J. et al.

Journal of acquired immune deficiency syndromes: JAIDS. Volume 77:Number 5 (2018) -- Wolters Kluwer

Online access

10
Material Type:
Article
Add to My workspace

Virologic outcomes in early antiretroviral treatment: HPTN 052

Eshleman, Susan H. et al.

HIV clinical trials. Volume 18:Issue 3 (2017); pp 100-109 -- Taylor & Francis, Taylor & Francis Group

Online access

Results 1 - 10 of 39  for Everything in this catalogue

results 1 2 3 4 next page

Refine Search Results

Refine my results

Access Options 

  1. Request to Reading Room  (27)
  2. Online: Reading Room only  (26)
  3. Purchase a copy  (21)
  4. Refine further open sub menu

Material type 

  1. Articles  (36)
  2. Books  (3)
  3. Refine further open sub menu

Creation date 

From To
  1. Before2005  (2)
  2. 2005To2006  (6)
  3. 2007To2015  (6)
  4. 2016To2018  (21)
  5. After 2018  (4)
  6. Refine further open sub menu

Language 

  1. English  (10)
  2. Unspecified  (1)
  3. Refine further open sub menu

Additional Features 

  1. Abstract  (26)
  2. No Abstract  (10)
  3. Refine further open sub menu

Searching Remote Databases, Please Wait